Business
Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits
Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogi...
About this update from Resverlogix Corp.
[{"type":"text","content":"Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsCalgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) (\"Resverlogix\", \"the Company\") today announced publication of an article, entitled, \"The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation,\" by Dr. Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40th peer-reviewed scientific journal article published by Resverlogix researchers on apabetalone's potential therapeutic benefits.Apabetalone's Publication Record:Articles on apabetalone have been published in some of the world's most prestigious scientific journals, including: Nature, Science, Cell, the Journal of the American Medical Association, Cardiovascular Diabetology and the Clinical Journal of the American Society of NephrologistsResverlogix researchers and our collaborators have published 40 articles on apabetalone in scientific journals, and including work by third-party researchers, there are more than 100 articles on apabetalone in the academic literatureThis body of work presents evidence of apabetalone's potential in the treatment of cardiovascular disease, diabetes, post-COVID-19 conditions, chronic kidney disease, and vascular cognitive impairment, as well as rare diseases such as pulmonary arterial hypertension, facioscapulohumeral muscular dystrophy, and Fabry's diseaseThe publications also cover a wide spectrum of topics from investigations of apabetalone's mechanism of action at a molecular level, to reports on large-scale clinical trials with thousands of participants\"We are very proud of our publication record on apabetalone,\" said Dr. Ewelina Kulikowski, Chief Scientific Officer at Resverlogix. \"Thanks to the dedicated work of our researchers, we have learned an incredible amount about this drug; how it works, why it's safe, and how it can potentially benefit people suffering from chronic disease.\"\"The depth and breadth of our knowledge of apabetalone is on full display in the forty scientific articles that we have published to date,\" said Donald McCaffrey, President and CEO at Resverlogix. \"We firmly believe that apabetalone will help chronic disease patients, we have publis...